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Abstract
Background: Basal-like breast cancer (BLBC) is a poorly characterised, heterogeneous disease. Patients are
diagnosed with aggressive, high-grade tumours and often relapse with chemotherapy resistance. Detailed
understanding of the molecular underpinnings of this disease is essential to the development of personalised
therapeutic strategies. Inhibitor of differentiation 4 (ID4) is a helix-loop-helix transcriptional regulator required for
mammary gland development. ID4 is overexpressed in a subset of BLBC patients, associating with a stem-like poor
prognosis phenotype, and is necessary for the growth of cell line models of BLBC through unknown mechanisms.
Methods: Here, we have defined unique molecular insights into the function of ID4 in BLBC and the related
disease high-grade serous ovarian cancer (HGSOC), by combining RIME proteomic analysis, ChIP-seq mapping of
genomic binding sites and RNA-seq.
Results: These studies reveal novel interactions with DNA damage response proteins, in particular, mediator of DNA
damage checkpoint protein 1 (MDC1). Through MDC1, ID4 interacts with other DNA repair proteins (γH2AX and
BRCA1) at fragile chromatin sites. ID4 does not affect transcription at these sites, instead binding to chromatin
following DNA damage. Analysis of clinical samples demonstrates that ID4 is amplified and overexpressed at a
higher frequency in BRCA1-mutant BLBC compared with sporadic BLBC, providing genetic evidence for an
interaction between ID4 and DNA damage repair deficiency.
Conclusions: These data link the interactions of ID4 with MDC1 to DNA damage repair in the aetiology of BLBC
and HGSOC.
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Background
Breast cancer is a heterogeneous disease. Gene expres-
sion signatures delineate five major subtypes with dis-
tinct pathologies, treatment strategies and clinical
outcomes [1, 2]. The basal-like subtype (BLBC), account-
ing for ~ 18% of diagnoses, is a subtype with particularly
poor prognosis, largely due to the molecular and clinical
heterogeneity of these tumours, and the corresponding
lack of targeted therapeutics. The molecular drivers of
BLBC are poorly understood, thus there are limited
available targeted therapies.
One such molecular driver of a subset of BLBCs is
mutation in the breast and ovarian cancer susceptibility
gene (BRCA1) [3, 4]. Mutations in BRCA1 occur in ap-
proximately 0.25% of European women, predisposing
them to breast and ovarian cancer, particularly to poor
prognosis subtypes including BLBC and high-grade ser-
ous ovarian cancer (HGSOC) [3]. These two subtypes of
cancer are similar in terms of their gene expression pro-
files and genetic dependencies, and thus present similar
sensitivity to therapeutic targeting [5–7]. BRCA1 has
many cellular functions including transcription and gene
splicing, yet is best known for its role in mediating DNA
damage repair [8, 9]. BRCA1 coordinates efficient repair
of double stranded DNA breaks through the homolo-
gous recombination (HR) pathway [9]. In the absence of
functional BRCA1, cells accumulate mutations and gen-
omic instability and demonstrate an increased frequency
of genomic rearrangements [10].
Another molecular driver of BLBC is the Helix-Loop-
Helix (HLH) transcriptional regulator inhibitor of differ-
entiation 4 (ID4). We and others have previously shown
ID4 to be important for both mammary gland develop-
ment and also for the aetiology of BLBC [11–13]. ID4 is
overexpressed in a subset of BLBC patients, marking pa-
tients with poor survival outcome, and is necessary for
the growth of BLBC cell lines [11, 14–21]. Precisely how
ID4 mediates this function in BLBC is unclear.
ID proteins (ID1–4) lack a basic DNA binding domain,
and thus, their classical mechanism of action is believed
to entail dominant-negative regulation of canonical
binding partners, basic HLH (bHLH) transcription fac-
tors. ID proteins dimerise with bHLH proteins and pre-
vent them from interacting with DNA, affecting the
transcription of lineage-specific genes [22–26]. Yet this
model of ID protein function is largely based on evi-
dence from studies of ID1–3 in non-transformed fibro-
blasts, neural and embryonic tissue. ID proteins are
tissue specific in their expression and function, and
hence, this model may not apply to all four ID proteins
across various tissues and in disease [25, 27–32]. Indeed,
contrary mechanisms have been described for ID2 in
liver regeneration, with ID2 interacting with chromatin
at the c-Myc promoter as part of a multi-protein
complex to repress c-Myc gene expression [33, 34], and
ID4 has been shown to bind to and suppress activity of
the ERα promoter and regions upstream of the ERα and
FOXA1 genes in mouse mammary epithelial cells [12].
These data suggest that despite lacking a DNA binding
domain, ID proteins may interact with chromatin com-
plexes under certain conditions. However, no studies
have systematically mapped the protein or chromatin
interactomes for any ID family member.
To this end, we applied chromatin immunoprecipitation-
sequencing (ChIP-seq) to interrogate the ID4-chromatin
binding sites and rapid immunoprecipitation and mass
spectrometry of endogenous proteins (RIME) to determine
the ID4 protein interactome. In addition, ID4 knockdown
and RNA-sequencing analysis was used to determine tran-
scriptional targets of ID4. These analyses reveal a novel link
between ID4 with the DNA damage repair apparatus.
Methods
Mammalian cell culture growth conditions
Cell lines were obtained from American Type Culture
Collection and verified using cell line fingerprinting.
HCC70 and HCC1937 cell lines were cultured in RPMI
1640 (Thermo Fisher Scientific) supplemented with 10%
(v/v) FBS, 20mM HEPES (Thermo Fisher Scientific) and
1mM Sodium Pyruvate (Thermo Fisher Scientific). MDA-
MB-468 and OVKATE cell lines were cultured in RPMI
1640 (Thermo Fisher Scientific) supplemented with 10%
(v/v) FBS, 20mM HEPES (Thermo Fisher Scientific) and
0.25% (v/v) insulin (Human) (Clifford Hallam Healthcare).
Cells stably transduced with SMARTChoice lentiviral vec-
tors were grown in the presence of 1 μg/mL puromycin.
Imaging
Immunohistochemistry images were obtained using an
inverted epifluorescence microscope (Carl Zeiss, ICM-
405, Oberkochem, Germany). Images were captured by
the Leica DFC280 digital camera system (Leica Micro-
systems, Wetzlar, Germany). The Leica DM 5500 Micro-
scope with monochrome camera (DFC310Fx) or Leica
DMI SP8 Confocal with 4 lasers (405 nm, 488 nm, 552
nm and 638 nm) and two PMT detectors were used to
capture standard fluorescent and confocal images.
SMARTChoice inducible lentiviral system
ID4 and control lentiviral shRNA constructs (SMARTch-
oice) were purchased commercially (Dharmacon, GE, La-
fayette, CO, USA). Successfully transfected cells were
selected using puromycin resistance (constitutive under
the humanEF1a promoter). For ID4 knockdown analysis,
HCC70 cells with SMARTChoice shID4 #1 #178657
(VSH6380-220912204), SMARTChoice shID4 #2 #703009
(VSH6380-221436556), SMARTChoice shID4 #3 #703033
(VSH6380-221436580), SMARTChoice shNon-targeting
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(VSC6572) and mock-infected cells were used. Cells were
treated with vehicle control or with 1 μg/mL doxycycline
for 72 h before harvesting protein and RNA directly from
adherent cells. The SMARTChoice shID4 #2 #703009
(VSH6380-221436556) produced the highest level of ID4
knockdown and was used for further analysis.
Non-lethal DNA damage induction with ionising radiation
Cells were seeded at 2.5 × 105 (HCC70) or 2.2 × 105
(MDA-MB-468) cells/well in a 6-well plate in normal
growth medium. One day post seeding, cells were exposed
to 2–5 Gy of ionising radiation using an X-RAD 320 Series
Biological Irradiator (Precision X-Ray, CT, USA). Cells
were returned to normal tissue culture incubation condi-
tions and harvested at designated time points.
Gene expression analysis
Total RNA was prepared for using the miRNeasy RNA
extraction kit (Qiagen), according to the manufacturer’s
instructions. cDNA was generated from 1000 ng RNA
using the Transcriptor First Strand cDNA Synthesis Kit
(Roche) using oligo-dT primers and following the manu-
facturer’s instructions. qPCR analysis was used to ana-
lyse mRNA expression levels using Taqman probes
(Applied Biosystems/Life Technologies) as per the man-
ufacturer’s specifications (Table 1) using an ABI PRISM
7900 HT machine. qPCR data was analysed using the
ΔΔCt method [35].
Protein analysis
Cells were lysed, unless specified, using RIPA [0.88% (w/
v) Sodium Chloride, 1% (v/v) Triton X-100, 0.5% (w/v)
Sodium Deoxycholate, 0.1% (w/v) SDS, 0.61% (v/v) Tris
(Hydroxymethyl) Aminomethane and protease and
phosphatase inhibitors (Roche)] or Lysis Buffer 5 (10
mM Tris pH 7.4, 1 mM EDTA, 150 mM NaCl, 1% Triton
X-100 and protease and phosphatase inhibitors). If re-
quired, protein was quantified using the Pierce BCA
Protein Assay Kit (Thermo Fisher Scientific) according
to the manufacturer’s instructions. Western blotting ana-
lysis was conducted as previously described [11]. MDC1
protein was analysed using 3–8% tris/acetate gels and
PVDF nitrocellulose membrane for MDC1 analysis
(BioRad). All other proteins were analysed using the LiCor
Odyssey system (Millenium Science, Mulgrave, VIC,
Australia). Protein expression was analysed using anti-
bodies targeting ID4 (Biocheck anti-ID4 rabbit monoclo-
nal BCH-9/82-12, 1:40,000), β-Actin (Sigma anti-Actin
mouse monoclonal A5441, 1:5000) and MDC1 (Sigma
anti-MDC1 mouse monoclonal M2444, 1:1000).
Co-immunoprecipitation
Co-immunoprecipitations (IP) were conducted using
10 μL per IP Pierce Protein A/G magnetic beads
(Thermo Fisher Scientific) with 2 μg of antibody: IgG
rabbit polyclonal (Santa Cruz sc-2027), ID4 (1:1 mix of
rabbit polyclonal antibodies: Santa Cruz L-20: sc-491
and Santa Cruz H-70: sc-13047) and MDC1 (rabbit poly-
clonal antibody Merck Millipore #ABC155). Beads and
antibody were incubated at 4 °C on a rotating platform
for a minimum of 4 h. Beads were then washed three
times in lysis buffer before cell lysate was added to the
tube. Lysates were incubated with beads overnight at
4 °C on a rotating platform. Beads were washed three
times in lysis buffer and resuspended in 2× NuPage sam-
ple reducing buffer (Life Technologies) and 2× NuPage
sample running buffer (Life Technologies) and heated to
85 °C for 10 min. Beads were separated on a magnetic
rack, and supernatant was analysed by western blotting
as described above.
Rapid immunoprecipitation and mass spectrometry of
endogenous proteins (RIME)
Cells were fixed using paraformaldehyde (PFA) (ProSci-
Tech, Townsville, QLD, Australia) and prepared for
RIME [36] and ChIP-seq [37, 38] as previously de-
scribed. Cross-linking was performed for 7 min for
RIME experiments and 10 min for ChIP-seq, ChIP-exo
and ChIP-qPCR experiments. Samples were sonicated
using a Bioruptor Standard (Diagenode, Denville, NJ,
USA) for 30–35 cycles of 30 s on/30 s off (sonication
equipment kindly provided by Prof. Merlin Crossley,
UNSW). IP was conducted on 60 (ChIP-seq/ ChIP-exo)
to 120 (RIME) million cells using 100 μL beads/20 μg
antibody. Correct DNA fragment size of 100–500 bp was
determined using 2% agarose gel electrophoresis.
Patient-derived xenograft tumour models were cross-
linked at 4 °C for 20 min in a solution of 1% Formalde-
hyde (ProSciTech), 50 mM Hepes–KOH, 100 mM NaCl,
1 mM EDTA, 0.5 mM EGTA and protease inhibitors (H.
Mohammed, personal communication). Samples (0.5 mg
of starting tumour weight) were dissociated using a Poly-
tron PT 1200E tissue homogeniser (VWR) and sonicated
Table 1 Genes analysed and the corresponding Taqman assay
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using the Branson Digital Sonifer probe sonicator (Bran-
son Ultrasonics, Danbury, CT, USA) with a microtip at-
tachment for 3–4 cycles of 10 × [0.1 s on, 0.9 s off].
Mass spectrometry analysis was conducted at the Aus-
tralian Proteomic Analysis Facility (APAF) at Macquarie
University (NSW, Australia) [39]. Briefly, samples were
denatured in 100 mM triethylammonium bicarbonate
and 1% w/v sodium deoxycholate; disulfide bonds were
reduced in 10 mM dithiotreitol and alkylated in 20mM
iodo acetamide, and proteins digested on the dynabeads
using trypsin. After C18 reversed phase (RP) StageTip
sample clean up, peptides were submitted to nano liquid
chromatography coupled mass spectrometry (MS)
(nanoLC-MS/MS) characterisation. MS was performed
using a TripleToF 6600 (SCIEX, MA, USA) coupled to a
nanoLC Ultra 2D HPLC with cHipLC system (SCIEX).
Peptides were separated using a 15-cm chip column
(ChromXP C18, 3 μm, 120 Å) (SCIEX). The mass spec-
trometer was operated in positive ion mode using a
data-dependent acquisition method (DDA) and data-
independent acquisition mode (DIA or SWATH) both
using a 60-min acetonitrile gradient from 5 to 35%.
DDA was performed of the top 20 most intense precur-
sors with charge stages from 2+ to 4+ with a dynamic
exclusion of 30 s. SWATH-MS was acquired using 100
variable precursor windows based on the precursor
density distribution in data-dependent mode. MS data
files were processed using ProteinPilot v.5.0 (SCIEX) to
generate mascot generic files. Processed files were
searched against the reviewed human SwissProt refer-
ence database using the Mascot (Matrix Science, MA,
USA) search engine version 2.4.0. Searches were con-
ducted with tryptic specificity, carbamidomethylation of
cysteine residues as static modification and the oxida-
tion of methionine residues as a dynamic modifica-
tion. Using a reversed decoy database, false discovery
rate was set to less than 1% and above the Mascot-
specific peptide identity threshold. For SWATH-MS
processing, ProteinPilot search outputs from DDA
runs were used to generate a spectral library for tar-
geted information extraction from SWATH-MS data
files using PeakView v2.1 with SWATH MicroApp
v2.0 (SCIEX). Protein areas, summed chromatographic
area under the curve of peptides with extraction FDR
≤ 1%, were calculated and used to compare protein
abundances between bait and control IPs.
Chromatin immunoprecipitation-quantitative real-time
PCR analysis
Chromatin immunoprecipitation (ChIP) was conducted
as described previously [37]; however, following over-
night IP, the samples were processed using a previously
described protocol [40].
DNA was purified then quantified using quantitative
real-time PCR analysis. Control regions analysed and
primers used are listed in Table S4.
Relative enrichment of each region/primer set was cal-
culated by taking an average of each duplicate reaction.
The input Ct value was subtracted from the sample Ct
value and the Ct converted using the respective PE for
each primer set. The relative ChIP enrichment is then
calculated by dividing the gene region of interest by the
specific control region that is negative for both ID4 and
H3K4Me3 binding (IFF01/NOP2 #1 primer). The for-
mula for this normalisation is below:
ΦCt ¼ Ctregion of interest−Ctinput region
ChIP enrichment ¼ PE −ΦCt region of interestð Þ½ −PE −ΦCt IFF01ð Þ½ 
A sample was considered to be enriched if the fold-
change over IgG control for each region was > 2.
Chromatin immunoprecipitation-sequencing
Chromatin immunoprecipitation and sequencing (ChIP-
seq) was conducted as previously described [37]. Samples
were prepared and sequenced at Cancer Research United
Kingdom (CRUK), Cambridge, UK. Antibody conditions
for ChIP are the same as those used for RIME, with the
addition of antibodies targeting H3K4Me3 (Active Motif
#39159) and γH2AX (Ser139) (1:1 mix of Cell Signalling
#2577 and Merck Millipore clone JBW301). Samples were
sequenced at CRUK using an Illumina HiSeq 2500 single-
end 50-bp sequencing. Quality control was conducted
using FastQC [41] and sequencing adapters trimmed
using cutadapt [42]. Reads were aligned using Bowtie for
Illumina v0.12.7 [43] followed by Sam-to-Bam conversion
tool [44] and alignment using Bwa v0.705a [44]. Align-
ment statistics were generated using samtools flagstat
[version 0.1.18 (r982:295)] [44]. ChIP-seq peaks were
called using the peak calling algorithm HOMER v4.0 and
MACS v1.4.2 [45, 46].
Chromatin immunoprecipitation-exonuclease sequen-
cing (ChIP-exo) was conducted as previously described
[38]. Samples were prepared and sequenced at CRUK.
qPCR analysis of ChIP DNA
Publicly available H4K3Me3 ChIP-sequencing data and
the ID4 ChIP-sequencing data generated in this project
were visualised using UCSC Genome Browser (genome.
ucsc.edu and [47]). Regions of positive and negative en-
richment were selected and the 500–1000-bp DNA se-
quence was imported into Primer3, a primer design
interface, web version 4.0.0 [48]. Primers were designed
with a minimum primer amplicon length of 70 bp.
Primers were confirmed to align with specific DNA seg-
ments by conducting an in silico PCR using UCSC Gen-
ome Browser (genome.ucsc.edu and [47]). Oligo primers
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were ordered from Integrated DNA Technologies
(Singapore). Primers were tested to determine adequate
primer efficiency (between 1.7 and 2.3). All assays were
set up using an EPmotion 5070 robot (Eppendorf, AG,
Germany) and run on an ABI PRISM 7900 HT machine
(Life Technologies, Scoresby, VIC, Australia). Briefly, re-
actions were performed in triplicate in a 384-well plate.
Each reaction consisted of 1 μL 5 μM Forward primer,
1 μL 5 μM Reverse primer, 5 μL SYBR Green PCR Mas-
termix (Thermo Fisher) and 3 μL DNA. A standard
curve was created using unsonicated, purified DNA ex-
tracted from the HCC70 cell line in 10-fold dilutions (1,
0.1, 0.01, 0.001, 0.0001).
PCR cycling was as follows: 1 cycle at 50 °C for 2 min,
1 cycle at 95 °C for 10 min, followed by 40 cycles of 95 °C
for 15 s and 60 °C for 1 min. A dissociation step was con-
ducted at 95 °C for 15 s and 60 °C for 15 s. Data was ana-
lysed and a standard curve created using SDS 2.3
software (Applied Biosystems). The slope was used to
calculate the PE using the qPCR Primer Efficiency Cal-
culator (Thermo Fisher Scientific, available at thermo-
fisher.com).
Patient-derived xenograft and histology
All experiments involving mice were performed in ac-
cordance with the regulations of the Garvan Institute
Animal Ethics Committee. NOD.CB17-Prkdcscid/Arc
mice were sourced from the Australian BioResources
Ltd. (Moss Vale, NSW, Australia). Assoc. Prof Alana
Welm (Oklahoma Medical Research Foundation) kindly
donated the patient-derived xenografts (PDX) models
used in this study. Models were maintained as described
elsewhere [49]. Tumour chunks were transplanted into
the 4th mammary gland of 5-week-old recipient
NOD.CB17-Prkdcscid/Arc mice. Tumours were harvested
at ethical endpoint, defined as having a tumour approxi-
mately 1 mm3 in size or deterioration of the body condi-
tion score. At harvest, a cross-section sample of the
tumour was fixed in 10% neutral buffered formalin (Aus-
tralian Biostain, Traralgon, VIC, Australia) overnight be-
fore transfer to 70% ethanol for storage at 4 °C before
histopathological analysis. The formalin fixed paraffin
embedded (FFPE) blocks were cut in 4-μm-thick sec-
tions and stained for ID4 (Biocheck BCH-9/82-12, 1:
1000 for 60 min following antigen retrieval using pres-
sure cooker 1699 for 1 min, Envision Rabbit secondary
for 30 min). Protein expression was scored by a patholo-
gist using the H-score method [50].
Fluorescent in situ hybridisation
Tissue sections were analysed using fluorescent in situ hy-
bridisation (FISH) to examine the genomic region encod-
ing ID4 (6p22.3). ID4 FISH Probe (Orange 552–576 nm,
Empire Genomics, NY, USA) was compared to the control
probe CEP6 (Chromosome 6, Green 5-Fluorescein dUTP).
This CEP6 probe marks a control region on the same
chromosome as ID4 and is used to normalise ID4 copy
number. Breast pathologist Dr. Sandra O’Toole oversaw
the FISH quantification for all samples.
Immunofluorescence and proximity ligation assays
Immunofluorescence
Cells were seeded on glass coverslips (Coverglass, 13
mm, VITLAB, Germany). At harvest, media was re-
moved, and cells were washed twice with PBS without
salts and fixed in 4% paraformaldehyde (PFA) (ProSci-
Tech) for 10 min. Cells were again washed twice with
PBS without salts (Thermo Fisher Scientific) before per-
meabilising for 15 min with 1% Triton-X (Sigma-Al-
drich) in PBS and then blocking with 5% BSA in PBS
without salts for 1 h at room temperature. Cells were
washed twice with PBS without salts, and antibodies
were applied overnight at 4 °C: ID4 (Biocheck BCH-9/
82-12, 1:1000), MDC1 (Sigma-Aldrich M2444, 1:1000),
BRCA1 (Merck Millipore (Ab-1), MS110, 1:250), γH2AX
(Ser139) (Merck Millipore clone JBW301 05-636, 1:300),
FLAG (Sigma-Aldrich M2, 1:500) and V5 (Santa Cruz
sc-58052, 1:500). Cells were washed twice with PBS
without salts; then, secondary antibodies were applied
for 1 h at room temperature. Cells were washed twice
with PBS without salts, with the second wash containing
DAPI (1:500 dilution) and phalloidin (1:1000 dilution)
(CytoPainter Phalloidin-iFluor 633 Reagent Abcam
ab176758). Cells were then mounted on slides using
4 μL of Prolong Diamond (Thermo Fisher Scientific).
Duolink proximity ligation assay analysis (PLA)
PLA was conducted using Duolink PLA technology with
Orange mouse/rabbit probes (Sigma-Aldrich, DUO92102)
according to the manufacturer’s instructions. Images were
captured using SP8 6000 confocal imaging with 0.4um Z-
stacks. Maximum projects were made for each image
(100–200 cells) and quantified using FIJI by ImageJ [51] as
described previously [52]. Quantification was conducted
on a minimum of 50 cells. Data is represented as number
of interactions (dots) per cell.
Quantification of DNA damage foci
Image quantification was conducted using FIJI v2.0.0
image processing software (Fiji is just ImageJ, available
at Fiji.sc, [51]) as previously described [52]. Four to five
images were taken of each sample. The DAPI channel
was supervised to enable accurate gating of cell nuclei
for application to other channels. Size selection (pixel
size 2000 to 15,000) and circularity (0.30–1.00) cut-offs
were used. Cells on the edge of the image were excluded
from the analysis. The number of DNA damage foci per
cell nucleus was calculated for approximately 100–200
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cells. The information for individual samples was




Samples were stratified into groups as follows: 42 BLBC
(negative for ERα, PR, HER2 and positive for CK5/6,
CK14 or EGFR), 14 triple-negative non-BLBC (negative
for ERα, PR, HER2, CK5/6, CK14 and EGFR) and 26
HER2-Enriched (negative for ERα and PR, positive for
HER2). BRCA1-mutation status in this cohort is un-
known; however, it is expected to occur in approxi-
mately 6.5% of BLBC patients [53]. Samples were
obtained under the Garvan Institute ethical approval
number HREC 08/145.
Kathleen Cuningham Foundation Consortium for research
into familial breast cancer (KConfab)
BRCA1-mutant BLBC was sourced from KConfab. A
total of 97 BRCA1-mutant BLBC cases were obtained
under the Garvan Institute ethical approval number
HREC 08/145.
Ovarian cancer
A total of 97 HGSOC cases were obtained under the Hu-
man Research Ethics Committee of the Sydney South East
Area Hospital Service Northern Section (00/115) [54].
Results
ID4 interacts with chromatin without regulating
transcription
To investigate the molecular function of ID4, we first ex-
amined ID4 protein expression and cellular localisation
across a panel of breast and ovarian cancer cell lines.
Ovarian cancer cell lines were included due to the estab-
lished molecular similarities between BLBC and HGSOC
[5–7]. Furthermore, evidence suggests ID4 may play an
important role in the aetiology of both BLBC and
HGSOC [11, 55]. As described previously [11], ID4 is
predominantly expressed by cell lines of the BLBC sub-
type (Figure S1A). Variable ID4 protein expression was
observed across the ovarian cell lines, and unlike in
BLBC, ID4 did not associate specifically with HGSOC,
the more aggressive ovarian cancer subtype. Four ID4
expressing models were selected for further analysis:
MDA-MB-468 (BLBC), HCC70 (BLBC), HCC1954
(HER2-Enriched) and OVKATE (HGSOC), because
these models represent different biological systems with
similar levels of ID4 expression.
ID4 predominantly localised to chromatin, as evi-
denced by distinct punctate staining in the nucleus, with
a proportion of ID4 staining overlapping with DAPI-low
nuclear regions (Fig. 1a), typical of uncondensed
euchromatin. Due to this localisation, and a previous re-
port of ID4 associating with enhancer regions in normal
mammary epithelial cells [12], chromatin immunopre-
cipitation and sequencing (ChIP-seq) was used to inter-
rogate whether, and how, ID4 binds chromatin in BLBC.
ID4 ChIP-seq was conducted on asynchronous HCC70
cells in three biological replicates and compared with
IgG ChIP and an input control. Western blot analysis
confirmed successful immunoprecipitation of ID4 (Fig-
ure S1B). ChIP-seq data was integrated by removing sig-
nal identified in the input and IgG controls and
examining the overlap between the three ID4 ChIP-seq
replicates. Remarkably, ID4 reproducibly associated with
seven sites across the genome (Figure S2A and Table
S1). Some of these were focussed, small binding events
typical of transcription factor binding. For example, ID4
binding to the transcription start site of FAIM and GBA
(140–230 bp) (Figure S2C) was typical of transcription
factor binding peaks. In other locations, ID4 binding was
spread over very large regions of DNA, up to 10 kb in
length, which is reminiscent of some histone marks, and
not transcription factor binding profiles. ID4 bound pri-
marily to gene bodies of the protein-coding genes ELF3
and ZFP36L1, the long non-coding RNAs NEAT1 and
MALAT1 and the microRNA host-gene MIRLET7BHG.
The MACS peak-calling algorithm identified multiple
peaks per gene for these genes, due to wide spread bind-
ing across the region (ELF3, NEAT1, MALAT1, MIR-
LET7BHG and ZFP36L1) (Fig. 1b and Figure S2C). This
binding is absent from intergenic regions (Fig. 1b).
Due to the large expanses of ID4 binding, ChIP-
exonuclease (ChIP-exo) was employed to provide higher
resolution mapping of ID4 binding. ChIP followed by exo-
nuclease digestion and DNA sequencing identifies precise
transcription factor binding sites with higher resolution
than traditional ChIP-seq [38]. ID4 ChIP-exo was con-
ducted in biological duplicate in HCC70 and HCC1954
breast cancer cell lines (Figure S3A and Table S1). Con-
sistent with the initial ChIP-seq experiment, we identified
significant enrichment of ID4 binding to the genomic re-
gions encoding NEAT1, MALAT1 and GBA (Figure S3B).
Signal was observed at ELF3 and ZFP36L1; however, these
regions were not identified through MACS analysis (Fig-
ure S3C). Additional ID4 peaks were identified in several
transfer RNAs (tRNA) (Fig. 1c) and within the gene bodies
of KDM4C and ERRFI1 (Figure S3D). This method was
unable to further resolve ID4-chromatin binding informa-
tion and the data resembled the ChIP-seq data. This sug-
gests that ID4 forms large contiguous and uninterrupted
interactions with expanses of chromatin. The ID4-bound
chromatin aligned with regions of high transcriptional ac-
tivity, co-localising with DNaseI hypersensitivity clusters,
active histone marks, and BRCA1 and POLR2A transcrip-
tion factor binding sites (Fig. 1d).
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Fig. 1 (See legend on next page.)
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ChIP-qPCR was used to validate ID4 binding in
HCC70, HCC1954 and MDA-MB-468 cell lines. Primers
to the genes of interest were designed to tile across mul-
tiple sites in each gene, with several regions enriched for
ID4 binding compared to input and IgG controls (Fig. 1e
and Figure S4). ChIP-qPCR validation from independent
ChIP experiments validated the findings made from the
unbiased ChIP-seq approaches.
To address the specificity of ID4 binding, ChIP-qPCR
analysis was conducted on HCC70 cell line modified
with the SMARTChoice doxycycline-inducible ID4 short
hairpin. Doxycycline treatment resulted in an 87% re-
duction in ID4 protein expression at 72 h (Figure S5).
ID4 knockdown reduced ID4-chromatin binding at a
majority of sites (Figure S6b-c), confirming the specific
binding of ID4 to these loci.
Although ID proteins are classically thought to be tran-
scriptional regulators, to date, no studies have reported a
systematic analysis of ID4 transcriptional targets. Hence,
to determine whether ID4 affects transcription in BLBC,
we analysed changes in gene expression using RNA-
sequencing (RNA-seq) following ID4 depletion using the
SMARTChoice model described above. This analysis was
also used to identify whether ID4 regulates the expression
of genes adjacent to ID4 chromatin interactions. Differen-
tial expression analysis revealed limited changes in gene
expression following loss of ID4, with only six genes iden-
tified as being differentially expressed (Table S2), indicat-
ing ID4 does not function as a transcriptional regulator in
this model. Loss of ID4 did not affect the expression of
the ID4-bound genes identified through ChIP-seq and
ChIP-exo analysis, as determined through RNA-seq and
qPCR (Fig. 1f). This suggests that ID4 has a transcription-
independent role on chromatin.
ID4 interacts with DNA damage response proteins
To understand how ID4 interacts with chromatin in the
absence of a known DNA interaction domain, endogenous
ID4 was purified from cells using the proteomic technique
rapid immunoprecipitation mass spectrometry of en-
dogenous proteins (RIME) [36]. Anti-ID4 and control IgG
were used for immunoprecipitations in biological triplicate
(each in technical duplicate or triplicate) followed by mass
spectrometry in the HCC70, MDA-MB-468, HCC1954
and OVKATE cell lines. Proteins were considered bona
fide ID4-binding targets if they appeared in two or more
technical and biological replicates and were not present in
any IgG controls (Fig. 2a).
RIME analysis identified cell line-unique and common
ID4-binding candidates (Fig. 2b and Table S3). In total,
1106 unique proteins were identified across the four cell
lines. Gene Set Enrichment Analysis (GSEA) of the puta-
tive ID4 binding partners showed enrichment for chro-
matin (DNA damage and transcription proteins and
histones) and RNA-associated gene sets (including RNA
splicing and processing factors) (Fig. 2c and Table S3).
This compliments the above ChIP-seq data, demonstrat-
ing that ID4 interacts with chromatin and nuclear ma-
chinery. The BRCA1-PCC network was the most
significantly enriched gene set in the ID4 purified prote-
ome (PCC: Pearson correlation coefficient, 101/852 ID4-
associated genes were present in the set of 1652 BRCA1-
associated genes; p = 6.47E−59) (Fig. 2c). This gene set
comprises networks controlling breast cancer suscepti-
bility [59]. Other gene sets originating from this previous
study [59], including the CHEK2-PCC and ATM-PCC,
were also identified as highly enriched, suggesting an as-
sociation between ID4 and DNA damage repair factors.
Across the entire RIME dataset, only one peptide
mapping to a bHLH protein, HEB (also known as
TCF12), was identified, in one of nine technical repli-
cates in the OVKATE cell line. We therefore con-
cluded that HLH proteins are not significant ID4
interactors in BLBC and HGSOC.
Six proteins were commonly identified in all four cell
lines: ID4, mediator of DNA damage checkpoint 1
(See figure on previous page.)
Fig. 1 ID4 binds to chromatin in BLBC cell lines and PDX models and does not regulate transcription. a Immunofluorescence analysis of ID4 protein
expression in the HCC70 BLBC cell line, blue; nuclear marker DAPI, magenta; cytoskeletal marker phalloidin, green; ID4. 20 μm scale. b Three technical
replicates of ID4 ChIP-seq analysis in HCC70 cell line. IgG ChIP-seq and Input controls are shown for comparison. ID4 binding to (i) the genomic region
encoding the long non-coding RNAs NEAT1 and MALAT1 and (ii) the protein coding gene ELF3. c ID4 binding to tRNA_Leu (uc021yth.1) in HCC1954
cell line measured by ChIP-exo. Identification of ID4 binding enrichment identified by MACS peak-calling algorithm. Chromosome location,
transcription start site (TSS) and Refseq information tracks displayed. Reads have been aligned to the human reference genome Hg19 and peaks called
using MACs peak calling algorithm (v2.0.9) [38]. Images contain ChIP-seq coverage data and the peaks called for each ID4 technical replicate and the
consensus peaks called for all three ID4 ChIP-seq technical replicate for selected gene regions. ID4 binding is shown in comparison to IgG and Input
data for the same region. Data visualised using IGV [56, 57]. Transcription Start Site (TSS) indicated with black arrow. d Alignment of ID4 ChIP-exo peaks
with DNAse hypersensitivity clusters, Transcription Factor ChIP and histone marks H3K27Ac and H3K4Me3 ChIP-seq at NEAT1 and MALAT1, UCSC
Genome Browser. e Box and whisker plot of ID4 ChIP-qPCR analysis in HCC70 cells. Multiple primers were designed to tile across the large ID4 binding
sites. ID4 binding normalised to input DNA and to a region not bound by ID4 (negative region) and represented as fold-change over IgG control.
Ratio paired t test, *p < 0.05. Whiskers indicate min to max. n = 4. f qRT PCR analysis of mRNA transcript expression of ID4-bound genomic regions
following depletion of ID4 in HCC70 cells using a lentiviral, doxycycline-inducible short hairpin RNA #2 (SMARTChoice). Data normalised to B2M
housekeeping gene and to HCC70 cells treated with vehicle control. One-way ANOVA, multiple comparisons test of control primer B2M with each
primer set. ***p < 0.001, ns = non-significant. Error bars represent standard error. n = 4
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(MDC1), disintegrin and metalloprotease domain 9 pro-
tein (ADAM9), Histidine Rich Glycoprotein (HRG), spli-
cing factor 3a subunit 2 (SF3A2) and spectrin repeat
containing nuclear envelope family member 3 (SYNE3).
The most highly enriched protein, MDC1, was the only
protein to be identified in all RIME technical and bio-
logical replicates in all four cell lines. MDC1 has many
cellular functions, including cell cycle control and tran-
scription [60, 61], yet is best characterised for its role in
the DNA damage response, where it associates with
DNA [62]. Of the other proteins identified, ADAM9 and
HRG affect cell motility, SYNE3 is important in cyto-
skeletal and nuclear organisation [63] and SF3A2 is re-
quired for pre-mRNA splicing and the generation of
alternative transcripts [64]. ID4 was previously suggested
to bind to mutant p53 and SRSF1 [65, 66], yet no evi-
dence was found of these associations in our analysis.
To validate these findings in a more clinically relevant
setting, we conducted ID4 RIME in patient-derived
xenograft (PDX) models of triple-negative breast cancer
[49]. Three ID4-expressing models (HCI001, HCI002,
HCI009) were selected for RIME analysis based on de-
tectable expression of ID4 (Fig. 2d). ID4 and MDC1
were the only targets identified in ID4 RIME in all three
xenograft models and absent in the IgG RIME (see Table
S3 for full list of proteins identified in PDX models).
This discovery proteomics was supported by quantitative
mass spectrometry analysis of the models using the sen-
sitive label-free quantitative proteomic method termed
SWATH (Sequential Window Acquisition of all THeor-
etical mass spectra) [67]. This analysis showed a high
abundance of both ID4 and MDC1 in all three PDX
models (Fig. 2d). Due to the robust identification of
MDC1 in the four cell lines and the subsequent
validation of this interaction in three PDX models, we
focused further studies on the functional importance of
the ID4-MDC1 relationship.
ID4-MDC1 binding was validated using independent
methods including immunoprecipitation with an anti-ID4
antibody and anti-MDC1 antibody, followed by western
blotting with an independent monoclonal ID4 or a MDC1
antibody (Fig. 2e). This co-immunoprecipitation ex-
periment confirmed the ID4-MDC1 interaction in
MDA-MB-468 cells.
ID4 interacts with DNA repair proteins at fragile
chromatin sites in a DNA damage-dependent manner and
regulates DNA damage signalling
To further explore the interaction between ID4 and
MDC1, we used proximity ligation assays (PLA), a quan-
titative measure of protein interaction in situ, and con-
firmed binding of ID4 with MDC1 in MDA-MB-468 cell
line. This interaction occurred predominantly in the cell
nucleus (Fig. 3a). Depletion of MDC1 using siRNA re-
sulted in reduction of the PLA signal to control levels
(Fig. 3b). PLA analysis was also used to test the associ-
ation of ID4 with γH2AX, as it is required for signalling
double-stranded DNA breaks and with BRCA1, as it is a
critical mediator of the homologous recombination (HR)
repair pathway. PLA analysis identified enrichment of
ID4 binding with MDC1, γH2AX and BRCA1 above
control levels in HCC70 and with MDC1 in OVKATE
cell lines (Figure S7).
To more closely examine the correlation between
DNA damage and ID4 complex association with chro-
matin, we used ionising radiation (IR) to induce DNA
damage in cells. Irradiation markedly increased ID4
chromatin binding, measured by ChIP-qPCR; up to 160-
(See figure on previous page.)
Fig. 2 ID4 binds to MDC1 and interacts with the BRCA1 network. a Schematic of ID4 and IgG RIME data analysis; ID4 and IgG
immunoprecipitations were conducted in technical duplicate or triplicate, and in biological triplicate. All proteins identified in the IgG controls
(for each biological replicate) were removed from each of the ID4 IPs as non-specific, background proteins. The remaining proteins were
compared across technical replicates to generate a list of medium-confidence proteins that were robustly identified in > 1 ID4 RIME technical
replicate. The biological replicates were then compared to generate a list of targets present in > 1 biological replicate in an individual cell line
(i.e., > 6 technical replicates conducted over three biological replicates). This resulted in the identification of 22 (HCC70), 21 (HCC1954), 21 (MDA-
MB-468) and 30 (OVKATE) proteins. Targets from the different cell lines were compared, identifying a list of ID4 interactors present across multiple
cell lines. b Venn diagram showing comparison of the high-confidence targets identified in all four cell lines: HCC70, HCC1954, MDA-MB-468 and
OVKATE. Common targets across the four cell lines are indicated. Overlap generated using Venny [58]. c Top six highest enriched gene sets
identified through Gene Set Enrichment Analysis (GSEA) of the ID4 proteome (1106 proteins) identified in (b) (all proteins identified in ID4 RIME
and not in IgG RIME), compared to C2 (curated gene sets), C4 (computational gene sets), C6 (oncogenic signatures), C7 (immunologic signatures)
and H (hallmark gene sets) gene sets. Proteins identified in > 1 technical replicate of ID4 RIME (and not in IgG RIME) were considered in GSEA
analysis. d, top: Immunohistochemistry analysis of ID4 protein expression across HCI001, HCI002 and HCI009 triple-negative PDX models, 100 μm
scale, bottom; SWATH proteomic analysis of ID4 and IgG RIME conducted on HCI001, HCI002, HCI009 PDX models. Heatmap showing
quantification of ID4 and MDC1 abundance, both significantly differentially expressed proteins in ID4 RIME compared with control IgG RIME (p
value < 0.05 and fold change > 2). RIME and SWATH were conducted on the same sample, one biological replicate per tumour. 100 μm scale. e
Immunoprecipitation was conducted on MDA-MB-468 cells prepared using the RIME protocol. Top: Input control and IgG (mouse and rabbit)
compared to IP with anti-ID4 antibodies and MDC1. Western blotting is shown using an independent monoclonal MDC1 antibody. Bottom: Input
control and IgG rabbit compared to IP with anti-ID4 antibodies and MDC1. Western blotting is shown using an independent monoclonal
ID4 antibody
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fold compared to undamaged controls at the NEAT1
gene, and 5–70-fold at ELF3, MALAT1, MIRLET7BHG,
ZFP36L1, GBA and various tRNAs (Fig. 3c and Figure
S8). This indicates that ID4 binding is specific and in-
duced by DNA damage. ChIP-qPCR for MDC1 similarly
showed induced binding to a majority of these sites in
damaged cells (Figure S8). Taken together, these results
suggest a positive correlation between DNA damage and
ID4-chromatin binding.
To investigate the functional role for ID4 in the DDR,
DNA damage was induced using IR and damage sensing
was monitored over time. Cells were treated with doxy-
cycline to deplete ID4 for 72 h (point of maximal ID4
knockdown) prior to treatment with ionising radiation.
Cells were fixed at 0, 15 min and 8 h following ionising
radiation, to examine the DNA damage response over
time. As previously reported [68], the number of γH2AX
foci in control cultures increased at 15 min post-IR and
remained high at 8 h (Fig. 3d), while the number of
53BP1 foci increased at 8 h following ionising radiation
(Fig. 3e). Upon ID4 depletion, formation of γH2AX and
53BP1 foci was significantly reduced at 8 h post-IR. This
Fig. 3 ID4 interacts with DNA damage proteins at fragile chromatin sites in a DNA damage-dependent manner. a Representative proximity
ligation assay (PLA) confocal images of ID4 and MDC1 interactions in MDA-MB-468 cells. siRNAs targeting MDC1 (siMDC1) and a scrambled
control (siControl) used to show specificity of the assay. PLA foci (green), DAPI (blue) and phalloidin (magenta). 20 μm scale. b Graph showing
quantification of PLA interactions between ID4 and MDC1 in cells treated with siControl and siMDC1. Data shown in comparison to the
interaction between ID4:V5 and ID4:FLAG treated with siControl. 50–100 cells captured per condition. Quantification of interactions (number of
dots/ cell). One-way ANOVA, multiple comparisons test. ****p < 0.0001. Error bars represent standard deviation. c ChIP-qPCR analysis of ID4
binding in untreated HCC70 cells compared to cells treated with ionising radiation (5 Gy with 5 h recovery time prior to fixation). ID4 binding
normalised to negative control region, input DNA and IgG control. Data for each gene region is shown for both untreated (left) and ionising
radiation-treated (right) cells, connected by a line. Representative of two independent experiments. Quantification of a time course of d γH2AX
and e 53BP1 DNA damage foci formation following ionising radiation. ID4 was depleted from cells using the SMARTChoice inducible shRNA
system following treatment with doxycycline for 72 h prior to treatment with 5 Gy ionising radiation at time 0 and allowed to recover for 0.25
and 8 h prior to analysis. Four to five images were taken for each condition; 100–200 cells in total. Number of foci per cell nucleus was calculated
using FIJI by ImageJ (Schindelin et al., 2012), and samples were then collated and analysed using the Pandas package in Python 3.5. Data is
normalised to 0 h, no DOX, no IR time point. n = 3–5, Student’s t test, *p < 0.05. Error bars represent standard error
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suggests that in the absence of ID4, the DNA was either
repaired more efficiently, or alternatively that the DNA
damage response was not triggered properly.
ID4 genetically interacts with BRCA1 mutation
The data presented earlier suggests an interaction be-
tween ID4 function and DNA damage pathways. Patients
with germline BRCA1 mutations are at elevated risk of
BLBC and HGSOC [3]. While BRCA1-associated cancers
often undergo BRCA1 loss of heterozygosity (LOH), re-
cent evidence suggests that mutation and copy number
change of additional genes, such as TP53, often occur
prior to, and may be required for, loss of the wildtype
BRCA1 allele [69]. We therefore assessed whether there
is evidence for copy number change of ID4 in (i) spor-
adic disease or (ii) in the context of familial breast can-
cer driven by germline BRCA1 mutation.
ID4 is reportedly amplified in sporadic BLBC [5, 6,
55]; however, these results are based on small cohorts
and imprecise array Comparative Genomic Hybridisa-
tion (aCGH) techniques, both of which affect accurate
determination of amplification frequency. To definitively
quantify ID4 amplification frequencies, we used fluores-
cent in situ hybridisation (FISH) in a clinical diagnostic
laboratory, a highly specific approach for analysing copy
number. FISH was applied to a discovery cohort of 82
sporadic oestrogen receptor-negative invasive ductal car-
cinomas: composed of 42 BLBC (negative for ERα, PR,
HER2 and positive for CK5/6, CK14 or EGFR), 14 triple-
negative non-BLBC (negative for Erα, PR, HER2, CK5/6,
CK14 and EGFR) and 26 HER2-Enriched (negative for
Erα and PR, positive for HER2) samples [11]. ID4 ampli-
fication was exclusive to the BLBC subtype with an
amplification frequency of ~ 10% (4/42 cases), and
amplification correlated with ID4 protein expression
(r = 0.265, p = 0.0088) (Fig. 4a and Figure S9).
We also examined whether ID4 is amplified in spor-
adic HGSOC. Analysis of 97 sporadic HGSOC cases [54]
showed a comparable rate of ID4 amplification relative
to sporadic BLBC of ~ 10% (10/97 in cases of HGSOC)
(Fig. 4e, g). However, these frequencies are lower than
that published using Array CGH [5, 6], potentially sug-
gesting that aCGH methods overestimate amplification
frequencies or that these are distinct clinical cohorts.
ID4 protein expression in HGSOC correlated with amp-
lification (r = 0.457 and p < 0.0001) (Fig. 4f, g).
To determine potential genetic interactions between
ID4 and BRCA1, ID4 copy number and protein expres-
sion was evaluated in 97 familial BLBCs from patients
with known germline BRCA1 mutations and compared
to the 42 unselected BLBC (which are not expected to
frequently carry BRCA1 germline mutations) described
above. ID4 was amplified at twice the frequency in
BRCA1-mutant BLBC (~ 22%, 21/97 cases) compared to
sporadic BLBC (~ 10%, 4/42 cases), indicating a selection
for ID4 amplification in cancers arising in patients carry-
ing a mutant BRCA1 allele (Fig. 4b, c). ID4 protein ex-
pression was also significantly higher in the BRCA1-
mutant BLBC compared to the sporadic BLBC cohort
(Fig. 4d). These data provide further evidence for an im-
portant role for ID4 in BLBC and HGSOC aetiology.
Discussion
By elucidating the drivers and dependencies of BLBC,
we aim to improve our understanding of this complex,
heterogeneous disease, potentially leading to the identifi-
cation of novel targets and therapeutics. Previous work
from our group and others has shown that ID4 acts as a
proto-oncogene in BLBC [11, 14–21]. ID4-positive BLBC
have a very poor prognosis, and depletion of ID4 re-
duced BLBC cell line growth in vitro and in vivo [11],
suggesting that ID4 controls essential, yet unknown in-
trinsic pathways in BLBC.
We have conducted the first systematic mapping of
the chromatin interactome of ID4 in mammalian cells.
Using ChIP-seq, we have identified novel ID4 binding
sites within the BLBC genome. ID4 bound to large re-
gions of chromatin, up to 10 kb in length, at a very small
number of loci, suggesting that ID4 is not binding as
part of a conventional transcriptional regulatory com-
plex. This conclusion is supported by the observation
that ID4 knockdown did not affect gene expression at
these loci. The regions identified through ChIP-seq were
typically the bodies of genes that are highly transcribed
and mutated in cancer [70, 71], characteristics of fragile,
DNA damage-prone sites. Interestingly, these sites pri-
marily encode non-coding RNA, including lncRNA,
microRNA precursors and tRNA. The lncRNA NEAT1
and MALAT1 are some of the most abundant cellular
RNAs and the genes encoding them undergo recurrent
mutation in breast cancer [72]. Furthermore, they are
upregulated in ovarian tumour cells and are associated
with higher tumour grade and stage and in metastases
[73]. The genomic loci encoding tRNAs are also highly
transcriptionally active, co-localising with DNaseI hyper-
sensitivity clusters and transcription factor binding sites,
including BRCA1 and POLR2A [74]. Transcriptional ac-
tivity is highly stressful and associated with genomic
stress and DNA damage [70]. Binding of ID4 to these
sites was increased upon DNA damage. Together, these
data suggest that ID4 binds preferentially to sites of ac-
tive transcription and DNA damage, consistent with its
interaction with MDC1.
We have conducted the most systematic and unbiased
proteomic analysis of binding partners for any ID family
member. RIME revealed hundreds of ID4 interacting
proteins, which were highly enriched for BRCA1-
associated proteins. Five novel proteins were found to
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interact with ID4 with high confidence in all 4 models
examined, namely MDC1, ADAM9, HRG, SF3A2 and
SYNE3. These warrant further investigation to examine
the role they may have in the mechanism of action of
ID4. Interestingly, no bHLH proteins were reproducibly
found in complex with ID4, although they are the ca-
nonical ID binding partners in certain non-transformed
cells [22–26]. This is unlikely to be a technical artefact,
as ID4-bHLH interactions are readily detected in non-
transformed mammary epithelial cells using the same
method (H. Holliday et al; Unpublished data). Rather,
ID4 may have alternate binding partners as a conse-
quence of downregulation of bHLH proteins in BLBC
(H. Holliday et al; Unpublished data).
ID4 has been demonstrated to be a member of a ribo-
nucleoprotein complex along with mutant p53, SRSF1
and lncRNA MALAT1 [66]. This complex promotes
splicing of VEGFA pre-mRNA, which signals in a para-
crine manner to macrophages and ultimately results in
tumour angiogenesis [65, 66, 75]. p53 and SRSF1 were
Fig. 4 ID4 is selectively amplified in cancers arising in germline BRCA1 mutation carriers. a ID4 amplification in sporadic and familial BLBC.
Example images of fluorescent in situ hybridisation (FISH) analysis of ID4 (red) and CEP6 centromeric control (green) copy number aberrations in
a cohort of 42 sporadic BLBCs. 10 μm scale. b Example images of FISH analysis of ID4 (red) and CEP6 centromeric control (green) copy number
aberrations in a cohort of 97 BRCA1-mutant BLBCs. 10 μm scale. c Percentage of ID4 amplified cases in sporadic and BRCA1-mutant BLBCs
presented in a and b. *p < 0.05 (two-sample t test). d Immunohistochemical analysis of ID4 protein expression in the sporadic and BRCA1-mutant
BLBCs presented in a and b. ID4 protein quantified using the H-score method. H-score = intensity of staining (on a scale from 0 to 3) ×
percentage of cells positive. p = 0.007 (Mann-Whitney two-tailed test). e Example images of FISH analysis of ID4 (red) and CEP6 centromeric
control (green) copy number aberrations in a cohort of 97 high-grade serous ovarian cancers. 10 μm scale. f Immunohistochemistry staining for
ID4 in HGSOC. Example images of ID4 high expressing (top) and ID4 low expressing (bottom) HGSOC. g ID4 H-score compared with
corresponding ID4:CEP6 FISH ratio. Assuming non-Gaussian distribution, H-score and FISH correlated with a value of r = 0.457 and Spearman
correlation p ≤ 0.0001
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not identified in our RIME analysis. This disparity
may be the consequence of methodological differences
such as fixation, cell lysis conditions and detection
techniques. It is possible that ID4 is a member of a
large complex encompassing several splicing factors
(including SF3A1 and SRSF1). The observations that
ID4 interacts with both the MALAT1 gene, as well as
MALAT1 lncRNA itself [66], suggests that ID4 and
MALAT1 function are intimately linked and warrants
further investigation.
MDC1, the most reproducible binding partner of ID4
identified through RIME analysis, is recruited to sites of
DNA damage to amplify the phosphorylation of H2AX
(to form γH2AX) and recruit downstream signalling
proteins [62]. Deficiency in MDC1, much like BRCA1,
results in hypersensitivity to double-stranded DNA
breaks [76]. MDC1 interacted with many of the sites of
chromatin interaction by ID4 in a DNA damage-
dependent manner. We also find ID4 in close proximity
of known MDC1 interactors, including BRCA1 and
γH2AX. These data suggest a model in which ID4 asso-
ciates with the DNA damage repair apparatus at sites of
genome instability or damage via its interaction with
MDC1. MDC1 was also recently found to associate with
ID3, suggesting that this is a conserved feature of ID
proteins [77]. How MDC1 binds ID4 is unknown; how-
ever, a quasi HLH domain [78] structure within MDC1
may enable interaction with the HLH domain of ID4. As
complex feedback mechanisms govern the DNA damage
response, further investigation is required to determine
whether ID4 association with MDC1 ultimately pro-
motes or impedes DNA repair.
BRCA1 has proposed functions as a transcription fac-
tor controlling differentiation in non-transformed cells
[74, 79], but a primary role in DNA repair in cancer [9].
Similarly, ID4 is an important regulator of stemness in
the developing mammary gland, acting to inhibit dif-
ferentiation [11, 12]. However, the results presented
here have uncovered an unexpected role for ID4 in
the DNA damage response in BLBC, suggesting a
similar dichotomy of function to BRCA1, that is, pri-
marily regulating transcription during development
whilst predominantly regulating the DNA damage re-
sponse in cancer. Transcription is a stressful cellular
process causing significant DNA damage and repair
[70]. Thus, a role for transcription factors in localis-
ing DNA damage machinery to chromatin may be an
important cellular capability.
Mutations in BRCA1 predispose carriers predomin-
antly to cancers of the breast and ovaries (mostly BLBC
and HGSOC), though the mechanism driving tumori-
genesis in these patients is still unclear. While many
BRCA1-associated cancers undergo LOH for the wild-
type BRCA1 allele, many acquire other genomic ‘hits’
prior to this event, which may be required for subse-
quent LOH [80]. In addition to reporting a biochemical
interaction between ID4 and MDC1, we also show a
novel genetic interaction with BRCA1, in that ID4 is
amplified at twice the frequency in BRCA1-mutant
BLBC compared to sporadic BLBC, making it one of the
most frequently amplified genes in that disease. A caveat
of this finding is that other cancer-associated genes, such
as E2F3, are located adjacent to ID4 at Chr6q22 and so
may also be a target of the amplification event.
Further work is required to understand the drivers of
ID4 amplification and its contribution to DNA repair;
however, at least 2 scenarios are possible. In the first,
ID4 acts to suppress DNA repair proficiency and so co-
operates with BRCA1 haploinsufficiency to promote gen-
omic instability and tumourigenesis. This is consistent
with the positive correlation between ID4 expression
and ‘BRCAness’ [15], a defect in BRCA1 function in the
absence of germline BRCA1 mutations [81]. However,
perhaps more likely is the opposing scenario, that ID4
amplification and overexpression promote DNA damage
repair, consistent with our observations of ID4 associ-
ation with MDC1 at fragile sites and the ongoing re-
quirement for ID4 in BLBC proliferation that we
previously reported [11]. In the case of BRCA1-
associated breast cancer, ID4 amplification, like TP53
mutation, may be permissive for subsequent BRCA1
LOH which is otherwise lethal [69], explaining the high
frequency of ID4 amplification in familial cancers. Fur-
ther resolving the function of ID4 in BLBC will require
detailed biochemical analysis of DNA repair functional
assays, genetic studies with ID4 knockout cells or ani-
mals and access to a large cohort of familial breast can-
cers with detailed gene copy number, BRCA1 mutation
and methylation data.
Conclusions
In summary, in this integrated analysis of ID4 func-
tion in BLBC and HGSOC, we show that ID4 local-
ises to DNA at sites of active transcription and DNA
damage, bridged through its biochemical interaction
with the DNA damage response machinery, namely
MDC1. Rather than regulating transcription at these
sites, our data points to a role of ID4 in the DNA
damage response. Finally, we establish a genetic inter-
action between BRCA1 and ID4, where ID4 is ampli-
fied at twice the frequency in BRCA1-mutant BLBC
compared to sporadic disease. Though further studies
our required to dissect the precise involvement of
ID4 in the DNA damage response, these novel in-
sights expand upon our current understanding of the
mechanism by which ID4 drives malignancy in breast
and ovarian cancer.
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Additional file 1: Figure S1. Analysis of ID4 protein expression across a
panel of breast and ovarian cell lines. (A) Western blotting analysis of ID4
protein expression across a panel of breast (top) and ovarian (bottom)
normal and cancer cell lines. A rabbit monoclonal antibody specific to
ID4 (Biocheck, BCH-9/82–12) was used for detection [11]. Two isoforms of
ID4 are detectable across the panel. β-Actin is shown as a loading con-
trol. Modifications to images indicated with vertical black line. Cell lines
selected for further analysis are indicated with a black square. Breast can-
cer subtypes and ovarian cancer histotypes indicated [82, 83]. (B) Western
blot validation of RIME protocol. MDA-MB-468 cells were processed using
the RIME protocol. Antibodies targeting ID4 (pooled polyclonal anti-
bodies) and IgG (rabbit species matched control) control were used for
immunoprecipitation. Western blot analysis for ID4 protein expression,
using an independent ID4 monoclonal antibody, following immunopre-
cipitation. Figure S2. ID4 ChIP-sequencing analysis of HCC70 cell line
identifies reproducible ID4-chromatin binding sites. (A) Table summarising
three biological replicates of ID4 ChIP-seq analysis in HCC70 cell line. (B)
10,000 bp resolution image of ID4 ChIP-seq technical replicate #1 binding
to MALAT1 gene. Red sequencing reads are aligned to the positive strand
(5′ - 3′), and blue to the negative strand of DNA (3′ - 5′). ID4 binding to
(C) left to right: GBA, FAIM, MIRLET7BHG, NEAT1 and ZFP36L1. The
chromosomal location, size of the gene and Refseq, human reference
genome, are displayed at the top of the image. Reads have been aligned
to the human reference genome Hg19 and peaks called using MACs
peak calling algorithm (v2.0.9) [38]. Images contain ChIP-seq coverage
data and the peaks called for each ID4 technical replicate and the con-
sensus peaks called for all three ID4 ChIP-seq biological replicate for se-
lected gene regions. ID4 binding is shown in comparison to IgG and
Input data for the same region. Data visualised using IGV [56, 57]. Tran-
scription Start Site (TSS) indicated with black arrow. Figure S3. ID4 ChIP-
exonuclease sequencing analysis of HCC70 and HCC1954 cell lines repro-
duces ChIP-seq analysis. (A) Table summarising ChIP-exonuclease sequen-
cing analysis of ID4 and IgG binding events in HCC70 and HCC1954
breast cancer cell lines. ID4 binding normalised as for ChIP-seq analysis.
ChIP-exo analysis of the HCC70 and HCC1954 breast cancer cell lines
showing ID4 binding to NEAT1, MALAT1 and GBA (B), ZFP36L1 and ELF3
(C), and KDM4C and ERRFI1 (D). Reads have been aligned to the human
reference genome Hg19 and peaks called using MACs peak calling algo-
rithm (v2.0.9) [38]. Images contain ChIP-exo coverage data and the peaks
called for each ID4 technical replicate and the consensus peaks called for
both ID4 ChIP-exo technical replicate for selected gene regions. ID4 bind-
ing is shown in comparison to IgG and input data for the same region.
Data visualised using IGV [56, 57]. The chromosomal location and size of
the gene are displayed at the top of the image. Below this, Refseq, hu-
man reference genome, displays the gene corresponding to particular
genomic loci. Transcription Start Site (TSS) indicated with black arrow.
Figure S4. Validation of ID4 binding to specific loci in HCC70, MDA-MB-
468 and HCC1954 cell lines. (A) Schematic of primer binding across ELF3
gene region. Primers 1–5 are scattered along the length of the ELF3 gene
ID4. ChIP-qPCR analysis in (B) HCC70 (n = 2–8), (C) MDA-MB-468 (n = 2)
and (D) HCC1954 (n = 2) cells. Multiple primers were designed to tile
across the large ID4 binding sites. ID4 binding normalised to input DNA
and to a region not bound by ID4 (negative region) and represented as
fold-change over IgG control. 1-Way-ANOVA of ID4 binding across all
primers compared to negative region: HCC70 p = 0.0001, MDA-MB-468
p = 0.549, HCC1954 p = 0.519. Figure S5. ID4 knockdown using
SMARTChoice inducible lentiviral knockdown system. Representative
western blot showing ID4 and β-Actin protein expression in wild-type
HCC70 cell line and HCC70 cells stably transfected with SMARTChoice
vectors containing doxycycline-inducible shRNAs targeting ID4 (shID4 #1,
#2 and #3) or non-targeting control region (shNTC). Cells treated with
and without DOX for 72 h. (B) Western blotting densitometry quantifica-
tion of ID4 protein expression across six biological replicates of ID4
knockdown following treatment with and without DOX for 72 h. ID4 ex-
pression normalised to β-ACTIN and no DOX control. Error bars measure
standard error, n = 4–6. (C) qRT-PCR analysis of ID4 RNA expression
matched to cells in (B). Data normalised to B2M housekeeping gene and
no DOX control. Error bars measure standard error, n = 4–6. Student’s t-
test compares shNTC with the other modified cell lines. ** p < 0.01, ****
p < 0.001. Figure S6. Validation of specificity of ID4-chromatin binding
using the SMARTChoice ID4 knockdown model. (A) Western blot showing
ID4 and β-Actin protein expression in HCC70 cells stably transfected with
shID4 #2 SMARTChoice vector treated with and without doxycycline for
72 h. (B) ID4 ChIP-qPCR analysis of cells from (A). ID4 binding normalised
to input DNA, to a region not bound by ID4 (negative region) and to the
IgG control. Data represented as fold-change over untreated cells. (C) rep-
licate of ID4 ChIP-qPCR analysis of HCC70 cells stably transfected with
shID4 #2 SMARTChoice vector treated with and without doxycycline for
72 h. Figure S7. Proximity ligation assay analysis identifies constitutive
and DNA damage-inducible binding of ID4 to DNA damage proteins.
PLA analysis of ID4 association with FLAG, MDC1, BRCA1 and γH2AX in
(A) HCC70 and (B) OVKATE cell line. Analysis is representative of approxi-
mately 150–200 cells of pooled from two independent experiments. 1-
way Anova p = 0.098. B, right; example image of ID4 and MDC1 PLA.
Quantification of interactions presented on right (number of dots/ cell).
10 μm scale. Figure S8. Ionising radiation increases DNA damage foci
formation and localisation of MDC1 to chromatin. Induction of DNA dam-
age using ionising radiation measured using immunofluorescence ana-
lysis in MDA-MB-468 cells for γH2AX (top) and MDC1 (bottom) foci
formation (5Gy with 5 h recovery time prior to fixation). Example images
on left, quantification of foci on right. Four to five images were taken for
each condition; 50–100 cells. 20 μm scale (B) Second replicate of HCC70
ID4 ChIP-qPCR. (C) ChIP-qPCR analysis of MDC1 positive control binding
following ionising radiation DNA damage induction. Data normalised as
for Fig. 3c, with data shown as fold-change compared to no-IR, n = 1.
Figure S9. ID4 is overexpressed and amplified at a higher frequency in
BRCA1-mutant BLBC. (A) Graph of ID4 protein expression measured by H-
score. Contains 97 BRCA1-mutant BLBC patients. (B) ID4 protein expres-
sion measured by immunohistochemistry H-score compared with corre-
sponding ID4:CEP6 FISH ratio. Assuming non-Gaussian distribution, H-
score and FISH correlated with a value of r = 0.265 and Spearman correl-
ation p value of < 0.00881.
Additional file 2: Table S1. ChIP-seq and ChIP-exo MACS peaks.
Additional file 3: Table S2. ID4 RNA-seq differentially expressed genes.
Additional file 4: Table S3. Putative ID4 interaction proteins identified
by RIME.
Additional file 5: Table S4. ChIP-qPCR primers.
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